Antidepressant medication

Phase 3Small molecule

Antidepressant medication is one of 148 small molecule programs targeting Acute Coronary Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

147

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Coronary SyndromeActive, not recruiting

Inflammatory ResponseActive, not recruiting

Major Depressive DisorderRecruiting

DepressionRecruiting

Acute Coronary SyndromePreclinical

Active, not recruiting

Inflammatory ResponsePreclinical

Active, not recruiting

Major Depressive DisorderPreclinical

Recruiting

DepressionPhase 3

Recruiting

Competition

Competitive Landscape

120 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

12 2

Ketalar

Boehringer Ingelheim

Phase 3

3 3

Clozaril

LLife Extension Foundation Inc.

Phase 3

1 4

Sunosi

AAxsome Therapeutics, Inc.

Phase 3

1 5

Lithobid

SSolvay Pharmaceuticals

Phase 3

1 6

Psilocybin

COMPASS Pathways

Phase 3

11 7

Esketamine Hydrochloride

TThe Second Hospital of Anhui Medical University

Phase 3

2 8

Antidepressant medication

HHarvard Medical School (HMS and HSDM)

Phase 3

1 9

Aticaprant

Johnson & Johnson

Phase 3

4 10

Selective Serotonin Reuptake Inhibitor

Johnson & Johnson

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Depression

NCT05944926

Q2 2028

PreclinicalRecruiting

Major Depressive Disorder

NCT06450704

Q4 2028

Phase 2Recruiting

Depression

NCT05002309

Clinical

Trials by Indication[1]

Depression4 trials

Medication Treatment for Depression in Nursing Home Residents

Completed·UUniversity of Pennsylvania··NCT00076622·94 enrolled

Treatment Interrupts Depression Early

Recruiting·NNova Scotia Health Authority·Phase 2·NCT05002309·100 enrolled

Stress Generation and Recurrent Depression: The Role of Differential Treatment Response

Completed·CCentre for Addiction and Mental Health·Phase 1·NCT00745017·72 enrolled

Show 1 more trial

Improving Outcomes in Depression in Primary Care in a Low Resource Setting

Recruiting·HHarvard Medical School (HMS and HSDM)·Phase 3·NCT05944926·1,500 enrolled

Pilot Study1 trial

OptimizeD Pilot Study

Completed·HHarvard Medical School (HMS and HSDM)·Phase 3·NCT06153004·76 enrolled

Major Depression1 trial

Patient Dimensions as Predictors of Varied Treatment Responses and Outcomes in Patients With Major Depression

Completed·CCentre for Addiction and Mental Health·Phase 2·NCT00744406·72 enrolled

Depressive Symptoms1 trial

Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults

Completed·NNew York State Psychiatric Institute·Phase 4·NCT01973283·100 enrolled

Acute Coronary Syndrome1 trial

Comparison of Depression Identification After Acute Coronary Syndrome: Quality of Life and Cost Outcomes

Completed·—·N/A·NCT01993017·1,501 enrolled

2 more indications

Intravenous1 trial

Antidepressant Medication for Reducing HIV Risk Behavior in Depressed Intravenous Drug Users

Completed·—·Phase 3·NCT00228007·265 enrolled

Major Depressive Disorder1 trial

Inflammatory and Brain Mechanisms and Clinical and Cognitive Effects of an Exercise Intervention in Major Depressive Disorder: a Randomised Longitudinal Clinical Trial.

Recruiting·FFundación de Investigación Biomédica - Hospital Universitario de La Princesa·Preclinical·NCT06450704·124 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Antidepressant medication. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antidepressant medication compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antidepressant medication. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Harvard Medical School (HMS and HSDM) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: HHarvard Medical School (HMS and HSDM)

Antidepressant medication

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2028

Q4 2028

Trials by Indication[1]

Depression4 trials

Pilot Study1 trial

Major Depression1 trial

Depressive Symptoms1 trial

Acute Coronary Syndrome1 trial

Intravenous1 trial

Major Depressive Disorder1 trial

References

Drug Info

Quick Facts

Related News